Aimovig is named as an intervention in 3 current clinical trials in our UK, USA, Germany, Spain, Italy, Belgium, Poland, Switzerland, Portugal, Canada, Japan, Austria and China registers. 2 are recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Amgen (1). The most-studied condition is Migraine.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
CGRP Inhibition, Autonomic Function, and Migraine
NCT04628429 · ClinicalTrials.gov ↗ · Episodic Migraine, Chronic Migraine
|
Observational | Recruiting | Medical University of Vienna | Austria |
|
China HeadAche DIsorders RegiStry
NCT05334927 · ClinicalTrials.gov ↗ · Headache Disorders, Primary, Migraine, New Daily Persistent Headache
|
Observational | Recruiting | Beijing Tiantan Hospital | China |
|
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
NCT03836040 · ClinicalTrials.gov ↗ · Migraine
|
Phase 3 | Active, closed | Amgen | UK, USA, Germany, Spain, Italy, Belgium, Poland, Switzerland, Portugal, Canada, Japan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Amgen | 1 |
| Medical University of Vienna | 1 |
| Beijing Tiantan Hospital | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our UK, USA, Germany, Spain, Italy, Belgium, Poland, Switzerland, Portugal, Canada, Japan, Austria and China registers name Aimovig (also registered as Erenumab 1) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in Austria and 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Amgen (1), Medical University of Vienna (1) and Beijing Tiantan Hospital (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Aimovig works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Aimovig works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Aimovig (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.